drugset / Trial / NCT01375491
Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans
Phase 4
Completed
39 enrolled
University of California, San Diego
National Center for Research Resources (NCRR) · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabRuth L. Kirschstein National Research Service Award · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Obesity is a heightened state of inflammation in which production of cytokines and matrix metalloproteinases (MMPs) result in loss of function of insulin receptors and insulin resistance. Doxycycline (DOX) is a potent MMP inhibitor. We hypothesize that DOX will enhance insulin sensitivity and decreases inflammation in obese participants with type 2 diabetes (DM2).
Timeline
- Start
- 2009-10
- Primary completion
- 2011-06
- Completion
- 2011-06
Publications
- Background DeLano FA, Schmid-Schonbein GW. Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension. 2008 Aug;52(2):415-23. doi: 10.1161/HYPERTENSIONAHA.107.104356. Epub 2008 Jul 7.
- Results Frankwich K, Tibble C, Torres-Gonzalez M, Bonner M, Lefkowitz R, Tyndall M, Schmid-Schonbein GW, Villarreal F, Heller M, Herbst K. Proof of Concept: Matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes. J Inflamm (Lond). 2012 Oct 1;9(1):35. doi: 10.1186/1476-9255-9-35.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxycycline | Small molecule | 100 mg | — |